Abcam (MEX:ABCM) Inventory-to-Revenue : 0.35 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Abcam Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Abcam's Average Total Inventories for the quarter that ended in Jun. 2023 was MXN1,525 Mil. Abcam's Revenue for the six months ended in Jun. 2023 was MXN4,399 Mil. Abcam's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.35.

Abcam's Inventory-to-Revenue for the quarter that ended in Jun. 2023 declined from Dec. 2022 (0.36) to Dec. 2022 (0.35)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Abcam's Days Inventory for the six months ended in Jun. 2023 was 266.19.

Inventory Turnover measures how fast the company turns over its inventory within a year. Abcam's Inventory Turnover for the quarter that ended in Jun. 2023 was 0.69.

Abcam Inventory-to-Revenue Historical Data

The historical data trend for Abcam's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam Inventory-to-Revenue Chart

Abcam Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec22

Inventory-to-Revenue

Get a 7-Day Free Trial

0.10

0.11

0.13

0.14

0.16

Abcam Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Jun22	Dec22	Jun23
Inventory-to-Revenue	Get a 7-Day Free Trial															0.30	0.29	0.30	0.36	0.35

Competitive Comparison of Abcam's Inventory-to-Revenue

For the Biotechnology subindustry, Abcam's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abcam's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abcam's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Abcam's Inventory-to-Revenue falls into.

Abcam Inventory-to-Revenue Calculation

Abcam's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

	Inventory-to-Revenue (A: Dec. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Jun. 2020 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )
=	( (1175.772	+	1614.772)	/	2 )	/	8589.163
=	1395.272					/	8589.163
=	0.16

Abcam's Inventory-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

	Inventory-to-Revenue (Q: Jun. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Dec. 2022 )	+	Total Inventories (Q: Jun. 2023 ))	/	count )	/	Revenue (Q: Jun. 2023 )
=	( (1614.772	+	1435.152)	/	2 )	/	4398.536
=	1524.962					/	4398.536
=	0.35

Abcam (MEX:ABCM) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Abcam's Days Inventory for the six months ended in Jun. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2023 )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
	=	1524.962	/	1045.518	*	365 / 2
	=	266.19

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Abcam's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2023 )	/	Average Total Inventories (Q: Jun. 2023 )
	=	1045.518	/	1524.962
	=	0.69

Abcam Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Abcam's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Abcam Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (MEX:ABCM) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX

Website

https://www.abcam.com

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.